Pharma Update
Astegolimab: First-in-class anti-ST2 mAb in COPD
Early results show benefit in key endpoints throughout broad patient population
Astegolimab (anti-ST2 mAb)
astegolimab
(anti-ST2)
IL-33
macrophage
neutrophil
anti IL-33
mast cell
ST2* cells
endothelium
eosinophil
progenitor
eosinophil
48-week exacerbation rate
4
Ph lla (COPD-ST2OP) results¹
Exacerbation rate at 48 weeks
RR 0.78
(95% CI 0-53-1-14)
p=0.195
AERR=22%
Adjusted mean change from baseline
in SGRQ-C total score (95% CI)
ANWAN
SGRQ mean change from baseline
Placebo group
Astegolimab group
Roche
•
•
Astegolimab binds both soluble ST2 and
•
membrane bound ST2 (IL-33) receptor
⚫ IL-33/ST2 blockade may impact airway
remodeling in COPD patients
•
#3 cause of global deaths; no biologics
currently approved in COPD
24
0-
Placebo group
Astegolimab group
Weeks
Ph lla (COPD-ST20P): AER reduction of -22% (-37% in EOS low), reduction in SGRQ of -3.3 and increased FEV₁
by +40 ml
.
Safe and well tolerated
•
Earlier Ph Il results in asthma with AER reduction of -43% (-54% in EOS low) support efficacy and safety
profile in broad population, including EOS low²
1 Yousuf et al. Lancet Respir. Med. 2022;10 (5):469-77; 2Kelsen et al. J Allergy Clin Immunol 2021;148(3)790-8; mAb-monoclonal antibody; ST2=suppression of tumorigenicity 2; IL-33-interleukin-33; COPD-chronic obstructive
pulmonary disease; EOS-eosinophils; RR-rate reduction; AER(R)-annualized exacerbation rate (reduction); SGRQ-St. George's respiratory questionnaire; FEV₁-forced expiratory value
111View entire presentation